We leverage human genetics
At Alector we find solutions that will work for patients. We follow the science and don’t subscribe to dogma.
Neurodegenerative diseases are incurable and debilitating conditions that result in progressive death of nerve cells.
Symptoms of neurodegeneration
Research rooted in genetics.
A deep understanding of human genetics and recent evidence generated in genome wide association studies led to our immuno-neurology therapeutic hypothesis.
Human genetic evidence supports the importance of the interaction between the brain and the innate immune system. For example, twenty-two of the top 25 risk genes for Alzheimer’s disease regulate immune function in the brain.
At Alector, our programs come from translating genetic insights into target and drug discovery.
Fluid biomarkers can include proteins, lipids or nucleotides (RNA or DNA) in any of the body fluids and can be used as safety markers, assessing target engagement, and quantifying therapeutic efficacy. In our studies, we measure fluid biomarkers in blood and in cerebrospinal fluid (CSF).
Fluid biomarker example:
Neurofilament light chain
Neurofilament light chain (NfL) is a component protein of the neuron cytoskeleton that provides structural support for neurons and plays a number of important roles in intracellular transport of proteins within the axons. When nerve cells are damaged, NfL is released into the CSF and into the blood. Thus, NfL protein can serve as an indicator of neuronal loss and disease progression in neurological disorders, such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
Imaging biomarkers can be used to measure the structure and function of the brain as well as protein aggregates in the brain known to be involved in disease. In our studies we leverage a variety of imaging tools to assess brain integrity.
Imaging biomarker example:
Volumetric MRI (vMRI) is a non-invasive brain imaging technique used to measure the volume and structural integrity of specific regions of the brain. People with neurodegenerative diseases such as AD or FTD have an increased annual rate of brain volume loss compared to age-matched individuals with healthy brains. vMRI can be used to measure the rate of brain volume loss and assess if the atrophy rate decreases in response to treatment with a product candidate.
Leverage human genetics and insights into neurology
Create a broad portfolio of targets and programs
Rapidly move programs from discovery into clinical trials